FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury DOI Creative Commons

Dezhu Gao,

Yu Shi,

Zhiliang Wang

et al.

Published: Dec. 2, 2024

Traumatic brain injury (TBI) is a complex disease that leads to significant mortality and disability worldwide each year. TBI disrupts the normal activity of kinases molecular signaling pathways, but effective therapeutic methods for patients remain limited. Nowadays, kinase inhibitors approved by Food Drug Administration (FDA) mainly cancer treatment have shown potential effects in TBI. Preclinical studies suggest their promoting recovery. There are fewer randomized clinical evaluate efficacy. We search FDA traumatic as keywords on websites analyze associated research. This review explores efficacy inhibitors, identifies limitations must be addressed future research advance application FDA-approved emphasizes promising potential.

Language: Английский

FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury DOI Creative Commons

Dezhu Gao,

Yu Shi,

Zhiliang Wang

et al.

Published: Dec. 2, 2024

Traumatic brain injury (TBI) is a complex disease that leads to significant mortality and disability worldwide each year. TBI disrupts the normal activity of kinases molecular signaling pathways, but effective therapeutic methods for patients remain limited. Nowadays, kinase inhibitors approved by Food Drug Administration (FDA) mainly cancer treatment have shown potential effects in TBI. Preclinical studies suggest their promoting recovery. There are fewer randomized clinical evaluate efficacy. We search FDA traumatic as keywords on websites analyze associated research. This review explores efficacy inhibitors, identifies limitations must be addressed future research advance application FDA-approved emphasizes promising potential.

Language: Английский

Citations

0